Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder

European Archives of Psychiatry and Clinical Neuroscience

Volumn 250, Issue 1, 2000, Pages 6-10

  Melkersson, Kristina ^a   Hulting, Anna Lena ^b  

^a ST GÖRAN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dopamine agonists; Neuroleptics; Prolactinoma; Psychotic disorder

Indexed keywords

BROMOCRIPTINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; LITHIUM CITRATE; NEUROLEPTIC AGENT; PERPHENAZINE; QUINAGOLIDE; ZUCLOPENTHIXOL;

ADULT; AMENORRHEA; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; IMPOTENCE; MALE; PARANOID PSYCHOSIS; PRIORITY JOURNAL; PROLACTIN RELEASE; PSYCHOSIS; VISUAL IMPAIRMENT;

EID: 0034070150     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007539     Document Type: Article

References (42)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders (DSM-III-R), 3rd ed, revised. American Psychiatric Press, Washington, DC
2. 1 receptor. J Neurochem 47 : 1822-1831
3. Asplund K, Hägg E, Lindqvist M, Rapp W (1982) Phenothiazine drugs and pituitary tumors. Ann Intern Med 96 : 533
4. Bang P, Eriksson U, Sara V, Wivall IL, Hall K (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: Improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 124 : 620-629
5. 2 receptors of rat cerebral cortex. Gen Pharmacol 17 : 57-62
6. Boyd A (1995) Bromocriptine and psychosis: A literature review. Psychiatr Q 66 : 87-94
7. Brismar K, Hulting AL, Werner S (1990) The growth hormone, prolactin and TSH response to TRH and L-dopa in patients with hyperprolactinaemia and a normal-sized sella turcica may denote a pituitary adenoma. J Intern Med 228 : 435-442
8. Calne DB, Williams AC, Neophytides A, Plotkin C, Nutt JG, Teychenne PF (1978) Long-term treatment of parkinsonism with bromocriptine. Lancet April 8 : 735-738
9. Cash R, Raisman R, Ploska A, Agid Y (1987) Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease. J Neurochem 49 : 1075-1083
10. Cerasi E, Della Casa L, Luft R, Roovete A (1966) Determination of human growth hormone (HGH) in plasma by a double antibody radioimmunoassay. Acta Endocrinol 53 : 101-120
11. 2 receptors in the rat brain: autoradiographic visualization using a high-affinity selective agonist ligand. J Neurosci 7 : 1352-1360
12. 2 receptors. J Neural Transm 62 : 231-248
13. 3H] CV 205-502. Brain Research 440 : 123-132
14. Daradkeh TK, Ajlouni KM (1988) The effect of neuroleptics on prolactinoma growth in a Jordanian schizophrenic girl. Acta Psychiatr Scand 77 : 228-229
15. Davison K, Bagley CR (1969) Schizophrenia-like psychoses associated with organic disorders of the CNS: a review of the literature. In: Herrington RN (ed) Current Problems in Neuropsychiatry. Brit J Psychiat special publication No. 4. Headley Bros Ltd, Ashford, Kent, pp 113-184
16. De Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 5 : 273-282
17. 2 dopamine receptor occupancy in patients treated with classical neuroleptic and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 : 538-544
18. Flickinger JC, Rush SC (1996) Linear accelerator therapy of pituitary adenomas. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone, Edinburgh, pp 475-483
19. Gonzales A, Michanie C (1992) Clozapine for refractory psychosis. J Am Acad Child Adolesc Psychiatry 31 : 1169-1170
20. Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, Halpern FS (1978) Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35 : 108-116
21. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine S (1981) Clozapine: plasma levels and prolactin response. Psychopharmacology 73 : 184-187
22. Leysen JE (1984) Receptors for neuroleptic drugs. Adv Hum Psychopharmacol 3 : 315-356
23. Lilford VA, Lilford RJ, Dacie JE, Rees LA, Browne PD, Chard T (1984) Long-term phenothiazine treatment does not cause pituitary tumours. Brit J Psychiatry 144 : 421-424
24. Luthman M, Jónsdóttir I, Skoog B, Wivall IL, Roos P, Werner S (1990) Monoclonal antibodies reveal circulating growth hormone of high molecular weight not detectable by conventional assays. Acta Endocrinol (Copenh) 123 : 317-325
25. 2 adrenoceptors of rat cerebral cortex. Eur J Pharmacol 91 : 363-369
26. Meise U, Fleischhacker W (1996) Perspectives on treatment needs in schizophrenia. Brit J Psychiatry 168 (Suppl 29) : 9-16
27. Melkersson K, Hulting AL, Hall K (1999) Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuroendocrin Lett 20 : 199-204
28. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33 : 279-286
29. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136 : 1550-1555
30. 2 pki values. J Pharmacol Exp Ther 251 : 238-246
31. Meltzer HY, Sachar EJ, Frantz AG (1975) Dopamine antagonism by thioridazine in schizophrenia. Biol Psychiatry 10 : 53-57
32. Molitch ME (1995) Clinical manifestations. In: Shlomo M (ed) The Pituitary: Prolactinoma. Blackwell Science. Inc., Oxford, pp 455-456
33. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry 152 : 1444-1449
34. Ovsiew F (1993) Contraindications to the use of antipsychotic drugs. Am J Psychiatry 150 : 1753-1754
35. Reilly PL (1996) Prolactinomas: surgical results and prognosis. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone, Edinburgh, pp 363-376
36. Robbins RJ, Kern PA, Thompson TL (1984) Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. Am J Med 76 : 921-923
37. Schwartz JC, Giros B, Martres MP, Sokoloff P (1992) The dopamine receptor family: molecular biology and pharmacology. Seminars in the Neurosciences 4 : 99-108
38. Serby M, Angrist B, Lieberman A (1978) Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. Am J Psychiatry 135 : 1227-1229
39. Steven WJ, Lamberts RM Macleod (1996) Prolactinomas: medical treatment. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone, Edinburgh, pp 431-441
40. Turner TH, Cookson JC, Wass JAH, Drury PL, Price PA, Besser GM (1984) Psychotic reactions during treatment of pituitary tumours with dopamine agonists. Br Med J 289 : 1101-1103
41. Weingarten JC, Thompson TL (1985) The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry 7 : 364-366
42. Werder K (1996) Prolactinoma: clinical findings and endocrinology. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary Adenomas. Churchill Livingstone, Edinburgh, pp 111-126